UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF
THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )
Filed by the Registrant x
Filed by a Party other than the Registrant ¨
Check the appropriate box:
| ¨ | Preliminary Proxy Statement |
| ¨ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ¨ | Definitive Proxy Statement |
| x | Definitive Additional Materials |
| ¨ | Soliciting Material Pursuant to §240.14a-12 |
Nabi Biopharmaceuticals
(Name of Registrant as Specified in its Charter)
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
| ¨ | No fee required. |
| ¨ | Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
| (1) | Title of each class of securities to which transaction applies: |
| (2) | Aggregate number of securities to which transaction applies: |
| (3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): |
| (4) | Proposed maximum aggregate value of transaction: |
| (5) | Total fee paid: |
| x | Fee paid previously with preliminary materials. |
| ¨ | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
| (1) | Amount Previously Paid: |
| (2) | Form, Schedule or Registration Statement No.: |
| (3) | Filing Party: |
| (4) | Date Filed: |
|
NEWS RELEASE |
Investor Relations
301-770-3099 | www.nabi.com
FOR IMMEDIATE RELEASE
RiskMetrics Group and Glass Lewis & Co. Support Nabi Biopharmaceuticals’
Proposed NicVAX Option and License Agreement
Rockville, MD, February 18, 2010 – Nabi Biopharmaceuticals (Nasdaq: NABI) (the “Company”) announced today that RiskMetrics Group (ISS) and Glass Lewis & Co., two of the nation’s leading independent proxy advisory firms, recommend that stockholders of the Company vote “FOR” the Company’s exclusive option and license agreement for NicVAX®, (Nicotine Conjugate Vaccine) with GlaxoSmithKline Biologicals S.A., dated as of November 13, 2009, and the transactions contemplated thereby. ISS and Glass Lewis provide voting advice to hundreds of institutional investors, mutual and pension funds and other fiduciaries.
“The recommendations of these two leading independent proxy advisory firms confirm our Board of Directors’ unanimous view that the proposed NicVAX exclusive option and license agreement is in the best interests of our stockholders,” said Dr. Raafat Fahim, President and Chief Executive Officer of Nabi Biopharmaceuticals. “We urge all of our stockholders to vote “FOR” the NicVAX option and license agreement and the transactions contemplated thereby.”
Stockholders are encouraged to read the Company’s definitive proxy materials in their entirety as they provide, among other things, a detailed discussion of the process that led to the proposed NicVAX option and license agreement and reasons behind the Board of Directors’ unanimous recommendation that stockholders vote “FOR” the NicVAX option and license agreement and the transactions contemplated thereby. Stockholders who have questions about the NicVAX option and license agreement and the transactions contemplated thereby or need assistance in submitting their proxy or voting their shares should contact the Company’s proxy solicitor, Morrow & Co., LLC, toll free at 1-800-662-5200.
The Company’s special meeting of stockholders is scheduled for Tuesday, March 2, 2010, at 10:00 a.m., local time, at the Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, Maryland. Stockholders of record at the close of business on January 25, 2010 are entitled to notice of and to vote at the special meeting.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop products that target serious medical conditions in the areas of nicotine addiction and gram-positive bacterial infections. Nabi Biopharmaceuticals is currently developing NicVAX® (Nicotine Conjugate Vaccine), an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse. The company is headquartered in Rockville, Maryland. For additional information about Nabi Biopharmaceuticals, please visit www.nabi.com.
# # #